BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hypertrophic Cardiomyopathy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hypertrophic Cardiomy
 opathy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07023614-658@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IMB-101 (Ninerafaxstat): Phase 2 readout est. (NCT07023614)
DESCRIPTION:IMB-101 (Ninerafaxstat)\, phase 2\, Hypertrophic Cardiomyopathy
 .\nStudy: A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in 
 Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy\nEst
 imated primary completion: December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ninerafaxstat#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07023614
URL:https://assetmemo.bio/drug/ninerafaxstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06481891-314@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06481891)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Hypertrophic Cardiomyopathy.
 \nStudy: A Study to Evaluate the Efficacy and Safety of Sotagliflozin in S
 ymptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06481891
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021963-11075@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-1893: Phase 2 readout est. (NCT07021963)
DESCRIPTION:HRS-1893\, phase 2\, Hypertrophic Cardiomyopathy.\nStudy: A Cli
 nical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic C
 ardiomyopathy\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-1893#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07021963
URL:https://assetmemo.bio/drug/hrs-1893#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848506-10786@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT04848506)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: Open-label Extension Study to Evaluate the Long-term Safety and To
 lerability of Aficamten in Adults With HCM\nEstimated primary completion: 
 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aficamten
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048
 48506
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940777-660@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290721
DTEND;VALUE=DATE:20290722
SUMMARY:Camzyos (Mavacamten): Phase 3 readout est. (NCT07940777)
DESCRIPTION:Camzyos (Mavacamten)\, phase 3\, Hypertrophic Cardiomyopathy.\n
 Study: A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults
  With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HC
 M)\nEstimated primary completion: 21 July 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mavacamten#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07940777
URL:https://assetmemo.bio/drug/mavacamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412666-10786@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT06412666)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: A Study to Evaluate the Effect of Aficamten in Pediatric Patients 
 With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).\nEstimate
 d primary completion: January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/aficamten#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06412666
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
